🚀 VC round data is live in beta, check it out!
Elite Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Elite Pharmaceuticals and similar public comparables like Tectonic Therapeutic, GlaxoSmithKline Pakistan, Assembly Biosciences, YungShin Global Holding and more.
Elite Pharmaceuticals Overview
About Elite Pharmaceuticals
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Founded
1997
HQ
Employees
68
Website
Sectors
Financials (FY)
EV
$426M
Elite Pharmaceuticals Financials
Elite Pharmaceuticals reported last fiscal year revenue of $84M and EBITDA of $3M.
In the same fiscal year, Elite Pharmaceuticals generated $40M in gross profit, $3M in EBITDA, and had net loss of ($4M).
Elite Pharmaceuticals P&L
In the most recent fiscal year, Elite Pharmaceuticals reported revenue of $84M and EBITDA of $3M.
Elite Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $84M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $40M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA | — | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 3% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 25% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (5%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Elite Pharmaceuticals Stock Performance
Elite Pharmaceuticals has current market cap of $441M, and enterprise value of $426M.
Market Cap Evolution
Elite Pharmaceuticals' stock price is $0.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $426M | $441M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialElite Pharmaceuticals Valuation Multiples
Elite Pharmaceuticals trades at 5.1x EV/Revenue multiple, and 149.7x EV/EBITDA.
Elite Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Elite Pharmaceuticals has market cap of $441M and EV of $426M.
Equity research analysts estimate Elite Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elite Pharmaceuticals has a P/E ratio of (102.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $441M | XXX | $441M | XXX | XXX | XXX |
| EV (current) | $426M | XXX | $426M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 149.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 20.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 10.6x | XXX | XXX | XXX |
| P/E | — | XXX | (102.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 86.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Elite Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Elite Pharmaceuticals Margins & Growth Rates
Elite Pharmaceuticals' revenue in the last fiscal year grew by 9%.
Elite Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Elite Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tectonic Therapeutic | XXX | XXX | XXX | XXX | XXX | XXX |
| GlaxoSmithKline Pakistan | XXX | XXX | XXX | XXX | XXX | XXX |
| Assembly Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| YungShin Global Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Verastem | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elite Pharmaceuticals M&A Activity
Elite Pharmaceuticals acquired XXX companies to date.
Last acquisition by Elite Pharmaceuticals was on XXXXXXXX, XXXXX. Elite Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Elite Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialElite Pharmaceuticals Investment Activity
Elite Pharmaceuticals invested in XXX companies to date.
Elite Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Elite Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Elite Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Elite Pharmaceuticals
| When was Elite Pharmaceuticals founded? | Elite Pharmaceuticals was founded in 1997. |
| Where is Elite Pharmaceuticals headquartered? | Elite Pharmaceuticals is headquartered in United States. |
| How many employees does Elite Pharmaceuticals have? | As of today, Elite Pharmaceuticals has over 68 employees. |
| Is Elite Pharmaceuticals publicly listed? | Yes, Elite Pharmaceuticals is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Elite Pharmaceuticals? | Elite Pharmaceuticals trades under ELTP ticker. |
| When did Elite Pharmaceuticals go public? | Elite Pharmaceuticals went public in 1998. |
| Who are competitors of Elite Pharmaceuticals? | Elite Pharmaceuticals main competitors are Tectonic Therapeutic, GlaxoSmithKline Pakistan, Assembly Biosciences, YungShin Global Holding. |
| What is the current market cap of Elite Pharmaceuticals? | Elite Pharmaceuticals' current market cap is $441M. |
| What is the current revenue of Elite Pharmaceuticals? | Elite Pharmaceuticals' last fiscal year revenue is $84M. |
| What is the current EV/Revenue multiple of Elite Pharmaceuticals? | Current revenue multiple of Elite Pharmaceuticals is 5.1x. |
| Is Elite Pharmaceuticals profitable? | No, Elite Pharmaceuticals is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.